Lipoid pneumonia medical therapy: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
(Created page with "__NOTOC__ {{lipoid pneumonia}} {{CMG}}; {{AE}} ==Overview== There is no treatment for [disease name]; the mainstay of therapy is supportive care. OR Supportive therapy for...")
 
No edit summary
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{lipoid pneumonia}}
{{lipoid pneumonia}}
{{CMG}}; {{AE}}
{{CMG}}; {{AE}} {{RG}}


==Overview==
==Overview==
There is no treatment for [disease name]; the mainstay of therapy is supportive care.
Treatment of lipoid pneumonia is not well studied and published experience is only with case reports
 
OR
 
Supportive therapy for [disease name] includes [therapy 1], [therapy 2], and [therapy 3].
 
OR
 
The majority of cases of [disease name] are self-limited and require only supportive care.
 
OR
 
[Disease name] is a medical emergency and requires prompt treatment.
 
OR
 
The mainstay of treatment for [disease name] is [therapy].
 
OR
 
The optimal therapy for [malignancy name] depends on the stage at diagnosis.
 
OR
 
[Therapy] is recommended among all patients who develop [disease name].
 
OR
 
Pharmacologic medical therapy is recommended among patients with [disease subclass 1], [disease subclass 2], and [disease subclass 3].
 
OR
 
Pharmacologic medical therapies for [disease name] include (either) [therapy 1], [therapy 2], and/or [therapy 3].
 
OR
 
Empiric therapy for [disease name] depends on [disease factor 1] and [disease factor 2].
 
OR
 
Patients with [disease subclass 1] are treated with [therapy 1], whereas patients with [disease subclass 2] are treated with [therapy 2].


==Medical Therapy==
==Medical Therapy==
*Pharmacologic medical therapy is recommended among patients with [disease subclass 1], [disease subclass 2], and [disease subclass 3].
*Treatment of [[lipoid pneumonia]] is not well studied and published experience is only with some case reports.<ref name="pmid8129503">{{cite journal| author=Spickard A, Hirschmann JV| title=Exogenous lipoid pneumonia. | journal=Arch Intern Med | year= 1994 | volume= 154 | issue= 6 | pages= 686-92 | pmid=8129503 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8129503  }}</ref><ref name="HaddaKhilnani2009">{{cite journal|last1=Hadda|first1=Vijay|last2=Khilnani|first2=Gopi C|last3=Bhalla|first3=Ashu S|last4=Mathur|first4=Sandeep|title=Lipoid pneumonia presenting as non resolving community acquired pneumonia: a case report|journal=Cases Journal|volume=2|issue=1|year=2009|pages=9332|issn=1757-1626|doi=10.1186/1757-1626-2-9332}}</ref><ref name="BeermannChristensson1984">{{cite journal|last1=Beermann|first1=B|last2=Christensson|first2=T|last3=Moller|first3=P|last4=Stillstrom|first4=A|title=Lipoid pneumonia: an occupational hazard of fire eaters.|journal=BMJ|volume=289|issue=6460|year=1984|pages=1728–1729|issn=0959-8138|doi=10.1136/bmj.289.6460.1728}}</ref><ref name="pmid9244843">{{cite journal| author=Amato GM, Novara V, Amato G| title=[Lipid pneumonia. Favorable outcome after treatment with intravenous immunoglobulins, steroids, cephalosporins]. | journal=Minerva Pediatr | year= 1997 | volume= 49 | issue= 4 | pages= 163-9 | pmid=9244843 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9244843 }} </ref><ref name="ChangChen1993">{{cite journal|last1=Chang|first1=H Y|last2=Chen|first2=C W|last3=Chen|first3=C Y|last4=Hsuie|first4=T R|last5=Chen|first5=C R|last6=Lei|first6=W W|last7=Wu|first7=M H|last8=Jin|first8=Y T|title=Successful treatment of diffuse lipoid pneumonitis with whole lung lavage.|journal=Thorax|volume=48|issue=9|year=1993|pages=947–948|issn=0040-6376|doi=10.1136/thx.48.9.947}}</ref><ref name="MarchioriZanetti2011">{{cite journal|last1=Marchiori|first1=Edson|last2=Zanetti|first2=Gláucia|last3=Mano|first3=Claudia Mauro|last4=Hochhegger|first4=Bruno|title=Exogenous lipoid pneumonia. Clinical and radiological manifestations|journal=Respiratory Medicine|volume=105|issue=5|year=2011|pages=659–666|issn=09546111|doi=10.1016/j.rmed.2010.12.001}}</ref><ref name="pmid26464746">{{cite journal| author=Lin J, Huang LL, Zhang JW, Ye MH, Feng JX| title=Endogenous lipoid pneumonia presenting as solitary pulmonary nodule: a case report. | journal=Int J Clin Exp Pathol | year= 2015 | volume= 8 | issue= 8 | pages= 9727-30 | pmid=26464746 | doi= | pmc=4583978 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26464746 }} </ref><ref name="SiasDaltro2009">{{cite journal|last1=Sias|first1=Selma M.A.|last2=Daltro|first2=Pedro A.|last3=Marchiori|first3=Edson|last4=Ferreira|first4=Angela S.|last5=Caetano|first5=Regina L.|last6=Silva|first6=Cleonice S.|last7=Müller|first7=Nestor L.|last8=Moreira|first8=Jose|last9=Quirico-Santos|first9=Thereza|title=Clinic and radiological improvement of lipoid pneumonia with multiple bronchoalveolar lavages|journal=Pediatric Pulmonology|volume=44|issue=4|year=2009|pages=309–315|issn=87556863|doi=10.1002/ppul.20918}}</ref>
*Pharmacologic medical therapies for [disease name] include (either) [therapy 1], [therapy 2], and/or [therapy 3].
*In case of exogenous [[lipoid pneumonia]], avoiding ongoing exposure and providing supportive care is the mainstay of treatment.
*Empiric therapy for [disease name] depends on [disease factor 1] and [disease factor 2].
*As anti-inflammatory agents, corticosteroids are good option as a therapeutic option.
*Patients with [disease subclass 1] are treated with [therapy 1], whereas patients with [disease subclass 2] are treated with [therapy 2].
*However, corticosteroids are not indicated in all cases and should be used with precautions if the lung injury is severe and ongoing.
===Disease Name===
*Lipoid pneumonia being successfully treated with immunoglobulins and whole-lung lavage.
 
*Repeated whole-lung lavage is especially useful in children.
* '''1 Stage 1 - Name of stage'''
** 1.1 '''Specific Organ system involved 1'''
*** 1.1.1 '''Adult'''
**** Preferred regimen (1): [[drug name]] 100 mg PO q12h for 10-21 days '''(Contraindications/specific instructions)''' 
**** Preferred regimen (2): [[drug name]] 500 mg PO q8h for 14-21 days
**** Preferred regimen (3): [[drug name]] 500 mg q12h for 14-21 days
**** Alternative regimen (1): [[drug name]] 500 mg PO q6h for 7–10 days 
**** Alternative regimen (2): [[drug name]] 500 mg PO q12h for 14–21 days
**** Alternative regimen (3): [[drug name]] 500 mg PO q6h for 14–21 days
*** 1.1.2 '''Pediatric'''
**** 1.1.2.1 (Specific population e.g. '''children < 8 years of age''')
***** Preferred regimen (1): [[drug name]] 50 mg/kg PO per day q8h (maximum, 500 mg per dose) 
***** Preferred regimen (2): [[drug name]] 30 mg/kg PO per day in 2 divided doses (maximum, 500 mg per dose)
***** Alternative regimen (1): [[drug name]]10 mg/kg PO q6h (maximum, 500 mg per day)
***** Alternative regimen (2): [[drug name]] 7.5 mg/kg PO q12h (maximum, 500 mg per dose)
***** Alternative regimen (3): [[drug name]] 12.5 mg/kg PO q6h (maximum, 500 mg per dose)
****1.1.2.2 (Specific population e.g. '<nowiki/>'''''children < 8 years of age'''''')
***** Preferred regimen (1): [[drug name]] 4 mg/kg/day PO q12h（maximum, 100 mg per dose）
***** Alternative regimen (1): [[drug name]] 10 mg/kg PO q6h (maximum, 500 mg per day)
***** Alternative regimen (2): [[drug name]] 7.5 mg/kg PO q12h (maximum, 500 mg per dose) 
***** Alternative regimen (3): [[drug name]] 12.5 mg/kg PO q6h (maximum, 500 mg per dose)
** 1.2 '''Specific Organ system involved 2'''
*** 1.2.1 '''Adult'''
**** Preferred regimen (1): [[drug name]] 500 mg PO q8h
*** 1.2.2 '''Pediatric'''
**** Preferred regimen (1): [[drug name]] 50 mg/kg/day PO q8h (maximum, 500 mg per dose)
 
* 2 '''Stage 2 - Name of stage'''
** 2.1 '''Specific Organ system involved 1 '''
**: '''Note (1):'''
**: '''Note (2)''':
**: '''Note (3):'''
*** 2.1.1 '''Adult'''
**** Parenteral regimen
***** Preferred regimen (1): [[drug name]] 2 g IV q24h for 14 (14–21) days
***** Alternative regimen (1): [[drug name]] 2 g IV q8h for 14 (14–21) days
***** Alternative regimen (2): [[drug name]] 18–24 MU/day IV q4h for 14 (14–21) days
**** Oral regimen
***** Preferred regimen (1): [[drug name]] 500 mg PO q8h for 14 (14–21) days
***** Preferred regimen (2): [[drug name]] 100 mg PO q12h for 14 (14–21) days
***** Preferred regimen (3): [[drug name]] 500 mg PO q12h for 14 (14–21) days
***** Alternative regimen (1): [[drug name]] 500 mg PO q6h for 7–10 days 
***** Alternative regimen (2): [[drug name]] 500 mg PO q12h for 14–21 days
***** Alternative regimen (3):[[drug name]] 500 mg PO q6h for 14–21 days
*** 2.1.2 '''Pediatric'''
**** Parenteral regimen
***** Preferred regimen (1): [[drug name]] 50–75 mg/kg IV q24h for 14 (14–21) days (maximum, 2 g)
***** Alternative regimen (1): [[drug name]] 150–200 mg/kg/day IV q6–8h for 14 (14–21) days (maximum, 6 g per day)
***** Alternative regimen (2):  [[drug name]] 200,000–400,000 U/kg/day IV q4h for 14 (14–21) days (maximum, 18–24 million U per day) '<nowiki/>'''''(Contraindications/specific instructions)''''''
**** Oral regimen
***** Preferred regimen (1):  [[drug name]] 50 mg/kg/day PO q8h for 14 (14–21) days  (maximum, 500 mg per dose)
***** Preferred regimen (2): [[drug name]] '''(for children aged ≥ 8 years)''' 4 mg/kg/day PO q12h for 14 (14–21) days (maximum, 100 mg per dose)
***** Preferred regimen (3): [[drug name]] 30 mg/kg/day PO q12h for 14 (14–21) days  (maximum, 500 mg per dose)
***** Alternative regimen (1):  [[drug name]] 10 mg/kg PO q6h 7–10 days  (maximum, 500 mg per day)
***** Alternative regimen (2): [[drug name]] 7.5 mg/kg PO q12h for 14–21 days  (maximum, 500 mg per dose)
***** Alternative regimen (3): [[drug name]] 12.5 mg/kg PO q6h for 14–21 days  (maximum,500 mg per dose)
** 2.2 '<nowiki/>'''''Other Organ system involved 2''''''
**: '''Note (1):'''
**: '''Note (2)''':
**: '''Note (3):'''
*** 2.2.1 '''Adult'''
**** Parenteral regimen
***** Preferred regimen (1): [[drug name]] 2 g IV q24h for 14 (14–21) days
***** Alternative regimen (1): [[drug name]] 2 g IV q8h for 14 (14–21) days
***** Alternative regimen (2): [[drug name]] 18–24 MU/day IV q4h for 14 (14–21) days
**** Oral regimen
***** Preferred regimen (1): [[drug name]] 500 mg PO q8h for 14 (14–21) days
***** Preferred regimen (2): [[drug name]] 100 mg PO q12h for 14 (14–21) days
***** Preferred regimen (3): [[drug name]] 500 mg PO q12h for 14 (14–21) days
***** Alternative regimen (1): [[drug name]] 500 mg PO q6h for 7–10 days 
***** Alternative regimen (2): [[drug name]] 500 mg PO q12h for 14–21 days
***** Alternative regimen (3):[[drug name]] 500 mg PO q6h for 14–21 days
*** 2.2.2 '''Pediatric'''
**** Parenteral regimen
***** Preferred regimen (1): [[drug name]] 50–75 mg/kg IV q24h for 14 (14–21) days (maximum, 2 g)
***** Alternative regimen (1): [[drug name]] 150–200 mg/kg/day IV q6–8h for 14 (14–21) days (maximum, 6 g per day)
***** Alternative regimen (2):  [[drug name]] 200,000–400,000 U/kg/day IV q4h for 14 (14–21) days (maximum, 18–24 million U per day)
**** Oral regimen
***** Preferred regimen (1):  [[drug name]] 50 mg/kg/day PO q8h for 14 (14–21) days  (maximum, 500 mg per dose)
***** Preferred regimen (2): [[drug name]] 4 mg/kg/day PO q12h for 14 (14–21) days (maximum, 100 mg per dose)
***** Preferred regimen (3): [[drug name]] 30 mg/kg/day PO q12h for 14 (14–21) days  (maximum, 500 mg per dose)
***** Alternative regimen (1):  [[drug name]] 10 mg/kg PO q6h 7–10 days  (maximum, 500 mg per day)
***** Alternative regimen (2): [[drug name]] 7.5 mg/kg PO q12h for 14–21 days  (maximum, 500 mg per dose)
***** Alternative regimen (3): [[drug name]] 12.5 mg/kg PO q6h for 14–21 days  (maximum,500 mg per dose)
 
==References==
==References==
{{Reflist|2}}
{{Reflist|2}}

Revision as of 02:49, 22 October 2019

Lipoid pneumonia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Lipoid pneumonia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Lipoid pneumonia medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Lipoid pneumonia medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Lipoid pneumonia medical therapy

CDC on Lipoid pneumonia medical therapy

Lipoid pneumonia medical therapy in the news

Blogs on Lipoid pneumonia medical therapy

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Lipoid pneumonia medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ramyar Ghandriz MD[2]

Overview

Treatment of lipoid pneumonia is not well studied and published experience is only with case reports

Medical Therapy

  • Treatment of lipoid pneumonia is not well studied and published experience is only with some case reports.[1][2][3][4][5][6][7][8]
  • In case of exogenous lipoid pneumonia, avoiding ongoing exposure and providing supportive care is the mainstay of treatment.
  • As anti-inflammatory agents, corticosteroids are good option as a therapeutic option.
  • However, corticosteroids are not indicated in all cases and should be used with precautions if the lung injury is severe and ongoing.
  • Lipoid pneumonia being successfully treated with immunoglobulins and whole-lung lavage.
  • Repeated whole-lung lavage is especially useful in children.

References

  1. ↑ Spickard A, Hirschmann JV (1994). "Exogenous lipoid pneumonia". Arch Intern Med. 154 (6): 686–92. PMID 8129503.
  2. ↑ Hadda, Vijay; Khilnani, Gopi C; Bhalla, Ashu S; Mathur, Sandeep (2009). "Lipoid pneumonia presenting as non resolving community acquired pneumonia: a case report". Cases Journal. 2 (1): 9332. doi:10.1186/1757-1626-2-9332. ISSN 1757-1626.
  3. ↑ Beermann, B; Christensson, T; Moller, P; Stillstrom, A (1984). "Lipoid pneumonia: an occupational hazard of fire eaters". BMJ. 289 (6460): 1728–1729. doi:10.1136/bmj.289.6460.1728. ISSN 0959-8138.
  4. ↑ Amato GM, Novara V, Amato G (1997). "[Lipid pneumonia. Favorable outcome after treatment with intravenous immunoglobulins, steroids, cephalosporins]". Minerva Pediatr. 49 (4): 163–9. PMID 9244843.
  5. ↑ Chang, H Y; Chen, C W; Chen, C Y; Hsuie, T R; Chen, C R; Lei, W W; Wu, M H; Jin, Y T (1993). "Successful treatment of diffuse lipoid pneumonitis with whole lung lavage". Thorax. 48 (9): 947–948. doi:10.1136/thx.48.9.947. ISSN 0040-6376.
  6. ↑ Marchiori, Edson; Zanetti, Gláucia; Mano, Claudia Mauro; Hochhegger, Bruno (2011). "Exogenous lipoid pneumonia. Clinical and radiological manifestations". Respiratory Medicine. 105 (5): 659–666. doi:10.1016/j.rmed.2010.12.001. ISSN 0954-6111.
  7. ↑ Lin J, Huang LL, Zhang JW, Ye MH, Feng JX (2015). "Endogenous lipoid pneumonia presenting as solitary pulmonary nodule: a case report". Int J Clin Exp Pathol. 8 (8): 9727–30. PMC 4583978. PMID 26464746.
  8. ↑ Sias, Selma M.A.; Daltro, Pedro A.; Marchiori, Edson; Ferreira, Angela S.; Caetano, Regina L.; Silva, Cleonice S.; Müller, Nestor L.; Moreira, Jose; Quirico-Santos, Thereza (2009). "Clinic and radiological improvement of lipoid pneumonia with multiple bronchoalveolar lavages". Pediatric Pulmonology. 44 (4): 309–315. doi:10.1002/ppul.20918. ISSN 8755-6863.

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Lipoid_pneumonia_medical_therapy&oldid=1585265"